Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vigabatrin

J P Mumford1, D J Cannon

  • 1Marion Merrell Dow Research Centre, Winnersh, England.

Epilepsia
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Vigabatrin (VGB) is a novel antiepileptic drug that increases brain GABA levels by inhibiting GABA-transaminase. It shows significant efficacy in partial seizures and infantile spasms, offering a new treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The moral foundations of a national medical service.

Journal. Medical Association of Eire·2010
Same author

A British Medical Association Lecture on RECENT ADVANCES IN THE PHYSIOLOGY OF MENSTRUATION.

British medical journal·2010
Same author

The wealth of a nation and the health of its workers and families.

Journal. Medical Association of Eire·2010
Same author

Stress incontinence in women.

Journal. Medical Association of Eire·2010
Same author

Traumatic rupture of the spleen.

Irish journal of medical science·2010
Same author

Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms.

Epilepsia·1999
Same journal

Factors associated with rapid pediatric acute seizure emergency treatment: Quality Improvement in Time to Treat Status Epilepticus baseline cohort.

Epilepsia·2026
Same journal

Outcome trajectories after pediatric epilepsy surgery vary by biopsychosocial phenotypes.

Epilepsia·2026
Same journal

Comparative risk of epilepsy with SGLT2 inhibitors versus incretin-based therapies in type 2 diabetes.

Epilepsia·2026
Same journal

Long-term mortality after status epilepticus: A 5-year analysis study.

Epilepsia·2026
Same journal

The Epilepsy-Cog study: Methods to establish a harmonized study of late onset epilepsy in a metacohort of six population-based cohorts in the United States.

Epilepsia·2026
Same journal

Systematic review and meta-analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life.

Epilepsia·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Epilepsy Research

Background:

  • Discovery of gamma-aminobutyric acid (GABA) as an inhibitory neurotransmitter.
  • Development of enzyme inhibition as a therapeutic strategy.
  • Conception of vigabatrin (VGB) as a GABA analogue.

Purpose of the Study:

  • To evaluate the efficacy and safety of vigabatrin (VGB) in epilepsy management.
  • To explore VGB's unique mechanism as a GABA-transaminase inhibitor.
  • To assess VGB's effectiveness in treatment-resistant partial seizures and infantile spasms.

Main Methods:

  • Vigabatrin (VGB) acts as an enzyme-activated irreversible inhibitor of GABA-transaminase.
  • Studies in animal models revealed a distinct activity spectrum compared to conventional antiepileptic drugs (AEDs).

Related Experiment Videos

  • Extensive human safety trials confirmed species-specific findings in animal studies do not occur in humans.

    • Main Results:

    • VGB is well-tolerated in clinical use.
    • Approximately 50% of patients with uncontrolled partial seizures experienced a 50% reduction in seizure frequency.
    • 4-5% of patients achieved seizure freedom.
    • VGB demonstrated particular effectiveness in managing infantile spasms in children.

    Conclusions:

    • Vigabatrin (VGB) offers a significant therapeutic improvement for epilepsy management.
    • VGB is effective for partial seizures refractory to other AEDs and for infantile spasms.
    • VGB is under development as a potential first-line antiepileptic treatment.